Skip to content
Medical Health Aged Care

Antidepressants, bowel cancer, ancient DNA, liver, heart, short stature, and Indigenous inequity

International Congress of Genetics in Melbourne. 3 mins read

Health genetic & genomic stories reported at the International Congress of Genetics in Melbourne.

·       Inequity in genomic health for Indigenous Australians

·       New guidelines released for achondroplasia, the most common form of disproportionate short stature

·       Repatriation of remains and land management: Who owns ancient DNA and its story of deep history?

·       The genomics of a liver or heart

·       A genetic test to choose the right antidepressant

·       "Māu Tēnā Kīwai o te Kete, Māku Tēnei:" Early detection of bowel cancer for Māori population

Read on for more information about each story. Contact Niall Byrne, [email protected], 0417-131-977

Inequity in genomic health for Indigenous Australians

Prabhathi Basnayake, University of Melbourne, reported on significant inequity in access to genetic services by Indigenous people in the NT, QLD and WA.

She is working in the Achieving Equity in Genomic Health (AEGH) for Indigenous Australians project to increase equity of access to genetic services by co-designing with genetic services, end user groups (all comprised entirely of Indigenous people) and the project reference group in the three jurisdictions.

New guidelines released for achondroplasia, the most common form of disproportionate short stature

On 1 May 2023, the Australian Government listed Voxzogo® (vosoritide) on the Pharmaceutical Benefits Scheme (PBS) – offering children and adolescents living with achondroplasia, the most common form of disproportionate short stature, the option of a medical treatment for the first time.

This has seen the local clinical community being faced with exploring how to access Government-subsidised treatment for a new patient population.

To support clinicians as they navigate this ‘new frontier’, a panel of the country’s leading experts have developed the first ‘Clinical management guidelines for the use of vosoritide in achondroplasia’, providing their recommendations to deliver optimum care for patients in this new setting.

Interviews available on request, with Professor Ravi Savarirayan, Co-Author of the local treatment guidelines, as part of the Australian Vosoritide Working Group. For interviews contact Tania Jayesuria, +61 404 094 744, [email protected].

Repatriation of remains and land management: Who owns ancient DNA and its story of deep history?

We can recover DNA from long dead plants, animals and humans, and use that DNA to extrapolate deep history, revealing the impact of human activity, pathogens and other factors on ancient ecosystem. Should we?

This type of research may be perceived as extractive neocolonialism and disrespectful by Indigenous communities.
A non-Indigenous researcher, Bastien Llamas is working towards developing respectful and sustainable paleogenomic research in Australia and Indonesia (a field of science based on the reconstruction and analysis of genomic information in extinct species).

“In Australia, ongoing paleogenomic research co-designed with Traditional owners shows that it can be used to help communities address some of their concerns (repatriation of remains) or answer some of their questions (pre-colonial biodiversity to guide land management),” says Bastien.

Bastien will receive the Genetics Society of Australia Ross Crozier Mid-Career award.

He is a researcher with the Australian Centre For Ancient DNA at the University of Adelaide, the National Centre for Indigenous Genomics at ANU and the Indigenous Genomics program at Telethon Kids.

The genomics of a liver or heart

Quin Wills is keeping donated human livers alive in ‘organ ICUs’ to study their genomics and develop AI models.

In the 20 years since the Human Genome Project, we have not seen an explosion of medicines born out of Big Data. Quin says that one explanation is that not all data is created equal.

He outlined how spatial and single-cell genomics are being combined with imaging AI, genetics and genetic screens to discover new drug targets using donor human organs maintained on machines in ’Organ ICUs’ to directly map human disease pathophysiology to genomic data.

His approach, at OchreBio bypasses animal models for better translatability.

A genetic test to choose the right antidepressant

Finding the right antidepressant can be a trial and error process, often prolonging treatment journey says Kathy Wu from St Vincent's Clinical Genomics.
She reported on the ALIGNED study which is investigating how a simple genetic test done through a cheek swab and other biomarkers can shorten this process, reduce side effects of antidepressants, and maximise chance of recovery through tailored prescription.  www.alignedstudy.org.au

"Māu Tēnā Kīwai o te Kete, Māku Tēnei:"

Early detection of bowel cancer for Māori population

Biomedical scientists and rural Indigenous communities in Aotearoa New Zealand are being united through a novel blood-based test for early detection of bowel cancer that can be delivered by communities, for communities to result in better health outcomes says Jordan Lima from the University of Otago.

The test looks for circulating tumour DNA.

 https://www.otago.ac.nz/biochemistry/news/otago747094.html 

 


Contact details:

  • Media welcome
  • For accreditation and interviews contact Niall Byrne, [email protected], 0417-131-977, or Sarah Brooker, [email protected], 0413-332-489.
  • Full Congress program at https://www.icg2023.com.au
  • Public program details at https://www.icg2023.com.au/public-program
  • Media releases at https://www.scienceinpublic.com.au/genetics

More from this category

  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 19:11
Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 12:24
La Trobe University

Cell death discovery could aid cancer treatments

LaTrobe researchers have made a groundbreaking discovery about the way dying cells are cleared from our bodies, which could have important impacts on recovery from diseases including cancer infection and inflammatory diseases. Traditionally, it was believed dying cells were broken into smaller pieces by the cell’s own internal machinery, enabling the pieces to be more easily removed from the body. However the study, led by scientists at the La Trobe Institute for Molecular Science and Research Centre for Extracellular Vesicles found that the process of dying cell fragmentation is actually assisted by neighbouring cells. Published in Science Advances, the study…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.